RVNC News and Press, Revance Therapeutics Inc. From 01/16/20

The following slide deck was published by Revance Therapeutics, Inc. in conjunction with this Read more ...

Introduction This forensic value analysis began with a check of four different algorithm scores of Tesla, Inc. (TSLA) at the request of members of my service back in October 2018. The question they asked at the time was, "what risk does Tesla, Inc. pose as an investment?" In an ad hoc query ...

Newport Beach, California-based Evolus (NASDAQ: EOLS ) is the newest entrant in the injectable aesthetics market. The business is strategized around a single product, a botulinum toxin marketed as Jeuveau. Their strategy focuses solely on the self-pay portion of the market, which we see as a l...

Today, we will be studying why Revance Therapeutics ( RVNC ) is an attractive investment for 2020. Company Overview Revance is a biotechnology company focused on developing innovative long-lasting neuromodulators. The company’s lead investigational product, DAXI (Daxibotulinumtoxi...

After the company announced an exclusive U.S. licensing deal to market multiple fillers used in cosmetic procedures,  Revance Therapeutics shares (NASDAQ: RVNC)  were up 13.1% at 12:30 p.m. EST on Friday. Investors were hoping Revance Therapeutics would make the leap from clinical-s...

Revance Therapeutics (NASDAQ: RVNC ) is up  3%  premarket on signing a U.S. distribution agreement with TEOXANE SA, a Swiss based private company for latter's Resilient Hyaluronic Acid (RHA) technology. More news on: Revance Therapeutics, Inc., Healthcare stocks news, Stoc...

- TEOXANE SA RHA® portfolio: first and only range of FDA-approved dermal fillers for correction of dynamic wrinkles - - Revance gains access to the growing $1.1B U.S. filler market with three differentiated products, and plans to launch in second quarter 2020 - - Fast-tra...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced that the company will participate in the 38th Annual J.P. Morgan Healthcare Conference, in San Francisco, CA. ...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today provided a corporate and product pipeline update and shared anticipated milestones for 2020. The company also announced tha...

Introduction I recently wrote an article about Revance Therapeutics' ( RVNC ) long-acting DAXI (DaxiBotulinumToxinA) and how the Phase III data was compelling enough to make me open a long position in RVNC. As an investor, I think it is paramount to always fully assess any competition that...